2025年上半年中药行业整体承压，万得（Wind）中药指数录得-0.79%，但优质中药上市公司却逆势上 扬，上半年同期天士力股价上涨9.7%，跑赢行业指数，显现市场对公司未来业绩保持乐观。8月15日晚 间，天士力（600535）发布的中报证实了市场预期，公司2025年上半年实现归母净利润7.75亿元，同比 增长16.97%，公司经营业绩与质量稳步提升，为后续的持续增长筑牢了坚实根基。 跑赢中药行业指数，持续为投资者创造价值 在近期召开的第二届中医药产业生态论坛上，行业专家坦言，随着政策环境、终端需求等方面的变化， 中医药行业面临跨周期挑战，部分中成药企业出现营收、净利润同步下滑的趋势。2025年上半年，万得 （Wind）中药指数下降0.79%。国家统计局数据显示，今年1-6月，全国规模以上工业企业医药制造业 营业收入12275.2亿元，同比下降1.2%；利润总额1766.9亿元，同比下降2.8%。 （文章来源：21世纪经济报道） 同时，公司公告拟向全体股东每10股派发现金红利2.1元（含税），持续为长期投资者提供价值回报。 截至2025年6月30日，公司总股本1,493,950,005股，以此计算合计拟派发现 ...

Group 1 - The traditional Chinese medicine (TCM) industry faced pressure in the first half of 2025, with the TCM index recording a decline of 0.79%, while Tianshili (600535) stock price increased by 9.7%, indicating market optimism about the company's future performance [1][2] - Tianshili reported a net profit attributable to shareholders of 775 million yuan in the first half of 2025, representing a year-on-year growth of 16.97%, with steady improvement in operational performance and quality [1][2] - The company plans to distribute a cash dividend of 2.1 yuan per 10 shares (tax included) to all shareholders, with a dividend payout ratio of 40.50% [1][3] Group 2 - The pharmaceutical manufacturing industry in China saw a revenue of 1,227.52 billion yuan in the first half of 2025, a year-on-year decrease of 1.2%, and total profits of 176.69 billion yuan, down 2.8% [2] - Tianshili's revenue for the first half of 2025 was 4.288 billion yuan, with pharmaceutical industrial revenue stable at 3.879 billion yuan and commercial revenue at 386 million yuan [2] - The company's debt-to-asset ratio decreased from 19.13% at the beginning of the year to 18.43% by the end of the reporting period, a reduction of 0.7 percentage points [2] Group 3 - Tianshili underwent a change in controlling shareholder to China Resources Sanjiu (000999) and completed the restructuring of its board of directors and supervisory board [4] - The company is actively implementing the management philosophy of China Resources, enhancing financial, human resources, and operational management integration, and initiating a "Fifteen Five" strategic planning process [4][5] - The company aims to enhance marketing collaboration with China Resources, integrating resources to improve market share and address distribution challenges in certain markets [4][5]